Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02269280

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied.

Status: 
Recruiting
Study Date: 
Wed, 10/01/2014 to Sat, 10/01/2022
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Azacitidine (AZA) Days 1 - 3 Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days. Other Names: 5-Azacytidine 5-AZA Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816 Azacytidine Drug: Decitabine (DAC) Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days. Other Name: Dacogen Other: Best Supportive Care (BSC) Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only. Drug: Azacitidine (AZA) Days 1 - 5 Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days. Other Names: 5-Azacytidine 5-AZA Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816 Azacytidine